alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 76–100 of 894 studies in Brain scans and imaging · tagged Brain Scans (page 4 of 36) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

What “Brain scans and imaging” covers

Brain scans and imaging — MRI, PET and other scans: what they show, how early, and how reliably.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Annals of Neurology 2004-01-21

This report describes the first human study of a novel amyloid-imaging positron emission tomography (PET) tracer, termed Pittsburgh Compound-B (PIB), in 16 patients with diagnosed mild AD and 9 controls. 3 key findings →

Participants: 16 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Nature neuroscience 2025-07-16

Tau positron emission tomography (PET) imaging allows in vivo detection of tau proteinopathy in Alzheimer's disease, which is associated with neurodegeneration and cognitive decline. 3 key findings →

Participants: 12,048 Evidence: low

Full summary, score breakdown and related studies → Original source

Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neurology 2014-07-08

Carriers (n = 39) and noncarriers (n = 36) had similar neuropsychological performance, except for lower Letter Digit Substitution Test scores in carriers. 5 key findings →

Design: case-control study Participants: 39 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2011-04-27

Changes in functional connectivity in DLB indicate patterns of activation that are distinct from those seen in AD and may improve discrimination of DLB from AD and cognitively normal individuals. 3 key findings →

Design: longitudinal study Participants: 88 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2019-11-22

Both AD and TDP/HS contribute to hippocampal volume loss in older-old persons, with TDP/HS more strongly associated with hippocampal volume than AD in Alzheimer dementia. 3 key findings →

Design: cohort study Participants: 232 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults

✓ Peer-reviewed alzhub usefulness score 62 out of 100. The American journal of psychiatry 2018-01-12

Higher amyloid beta burden was associated with increasing anxious-depressive symptoms over time in cognitively normal older individuals. 4 key findings →

Design: longitudinal study Participants: 270 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Reduced lean mass in early Alzheimer disease and its association with brain atrophy

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Archives of neurology 2010-04-01

Lean mass was reduced in persons with early AD compared with controls without dementia (F = 7.73; P = .006) after controlling for sex. 2 key findings →

Design: case-control study Participants: 70 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Neurology 2009-07-01

MRI and CSF provide complimentary predictive information about time to conversion from amnestic mild cognitive impairment to Alzheimer disease and combination of the 2 provides better prediction than either source alone. 3 key findings →

Participants: 399 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Archives of neurology 2008-01-01

High WMH was a predictor of progression from normal to MCI (adjusted hazard ratio [HR], 3.30; 95% confidence interval [CI], 1.33-8.17; P= .01) but not conversion from MCI to all-cause dementia. 2 key findings →

Design: cohort study Participants: 67 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months

✓ Peer-reviewed alzhub usefulness score 61 out of 100. International journal of geriatric psychiatry 2011-01-01

A framework for multi-centre MRI studies of Alzheimer's disease has been established consisting of a harmonized MRI acquisition protocol across centres, rigorous QC at both the sites and central data analysis hub and an automated image analysis pipeline. 4 key findings →

Design: longitudinal study Participants: 378 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest

✓ Peer-reviewed alzhub usefulness score 61 out of 100. NeuroImage 2006-03-14

In this study, researchers assessed the validity and reliability of an automated labeling system developed to subdivide the human cerebral cortex on magnetic resonance images into gyral based regions of interest. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Brain : a journal of neurology 2017-03-01

For amyloid positron emission tomography positive (Aβ+) subjects, flortaucipir neocortical standard uptake value ratio was significantly higher with more advanced clinical stage (Alzheimer's disease > mild cognitive impairment > older cognitively normal) and was significantly elevated for Aβ+ mild cognitive impairment and Alzheimer's disease subjects relative to the respective Aβ- subjects. 5 key findings →

Design: cross-sectional Participants: 217 Evidence: low

Full summary, score breakdown and related studies → Original source

SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline

✓ Peer-reviewed alzhub usefulness score 61 out of 100. PloS one 2022-11-03

Compared to CSF p-tau, meta-temporal, and averaged Braak tau PET ROIs, SPARE-Tau showed the strongest association with baseline ADAS-cog13 scores and diagnosis. 5 key findings →

Design: cross-sectional Participants: 587 Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed